200 related articles for article (PubMed ID: 37716979)
21. The response of PIK3CA/KRAS-mutant colorectal cancer stem-like cells to RGD-peptide FraC produced by the strawberry anemone: A promising water-soluble peptide-based inhibitor of metastasis-driver gene CXCR4, stem cell regulatory genes and self-renewal.
Sarkhosh-Inanlou R; Imani M; Sam MR
Biomed Pharmacother; 2020 Dec; 132():110807. PubMed ID: 33068939
[TBL] [Abstract][Full Text] [Related]
22. CRNDE, a long non-coding RNA responsive to insulin/IGF signaling, regulates genes involved in central metabolism.
Ellis BC; Graham LD; Molloy PL
Biochim Biophys Acta; 2014 Feb; 1843(2):372-86. PubMed ID: 24184209
[TBL] [Abstract][Full Text] [Related]
23. The current understanding on the impact of KRAS on colorectal cancer.
Meng M; Zhong K; Jiang T; Liu Z; Kwan HY; Su T
Biomed Pharmacother; 2021 Aug; 140():111717. PubMed ID: 34044280
[TBL] [Abstract][Full Text] [Related]
24. The lncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt/β-catenin signaling.
Han P; Li JW; Zhang BM; Lv JC; Li YM; Gu XY; Yu ZW; Jia YH; Bai XF; Li L; Liu YL; Cui BB
Mol Cancer; 2017 Jan; 16(1):9. PubMed ID: 28086904
[TBL] [Abstract][Full Text] [Related]
25. The Long Non-Coding RNA CRNDE Promotes Colorectal Carcinoma Progression by Competitively Binding miR-217 with TCF7L2 and Enhancing the Wnt/β-Catenin Signaling Pathway.
Yu B; Ye X; Du Q; Zhu B; Zhai Q; Li XX
Cell Physiol Biochem; 2017; 41(6):2489-2502. PubMed ID: 28472810
[TBL] [Abstract][Full Text] [Related]
26. Baseline MAPK signaling activity confers intrinsic radioresistance to KRAS-mutant colorectal carcinoma cells by rapid upregulation of heterogeneous nuclear ribonucleoprotein K (hnRNP K).
Eder S; Arndt A; Lamkowski A; Daskalaki W; Rump A; Priller M; Genze F; Wardelmann E; Port M; Steinestel K
Cancer Lett; 2017 Jan; 385():160-167. PubMed ID: 27793696
[TBL] [Abstract][Full Text] [Related]
27. Active Compound of
Song J; Seo H; Kim MR; Lee SJ; Ahn S; Song M
Molecules; 2020 Jun; 25(12):. PubMed ID: 32580297
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA-425-5p Expression Affects BRAF/RAS/MAPK Pathways In Colorectal Cancers.
Angius A; Pira G; Scanu AM; Uva P; Sotgiu G; Saderi L; Manca A; Serra C; Uleri E; Piu C; Caocci M; Ibba G; Zinellu A; Cesaraccio MR; Sanges F; Muroni MR; Dolei A; Cossu-Rocca P; De Miglio MR
Int J Med Sci; 2019; 16(11):1480-1491. PubMed ID: 31673240
[TBL] [Abstract][Full Text] [Related]
29. SNHG14 facilitates cell proliferation in colorectal cancer through targeting KRAS via Hippo-YAP signaling.
Shen M; Su Y; Song S; Liu D; Liu Z; Chen D; Pan Y; Zhang L; Xu X
Cell Mol Biol (Noisy-le-grand); 2023 Mar; 69(3):64-68. PubMed ID: 37300688
[TBL] [Abstract][Full Text] [Related]
30. Strategies to target energy metabolism in consensus molecular subtype 3 along with Kirsten rat sarcoma viral oncogene homolog mutations for colorectal cancer therapy.
Wang G; Wang JJ; Yin PH; Xu K; Wang YZ; Shi F; Gao J; Fu XL
J Cell Physiol; 2019 May; 234(5):5601-5612. PubMed ID: 30341899
[TBL] [Abstract][Full Text] [Related]
31. CRNDE promotes cell tongue squamous cell carcinoma cell growth and invasion through suppressing miR-384.
Ren Y; He W; Chen W; Ma C; Li Y; Zhao Z; Gao T; Ni Q; Chai J; Sun M
J Cell Biochem; 2019 Jan; 120(1):155-163. PubMed ID: 30242873
[TBL] [Abstract][Full Text] [Related]
32. NG25, a novel inhibitor of TAK1, suppresses KRAS-mutant colorectal cancer growth in vitro and in vivo.
Ma Q; Gu L; Liao S; Zheng Y; Zhang S; Cao Y; Zhang J; Wang Y
Apoptosis; 2019 Feb; 24(1-2):83-94. PubMed ID: 30515612
[TBL] [Abstract][Full Text] [Related]
33. The sodium channel subunit SCNN1B suppresses colorectal cancer via suppression of active c-Raf and MAPK signaling cascade.
Qian Y; Zhou L; Luk STY; Xu J; Li W; Gou H; Chen H; Kang W; Yu J; Wong CC
Oncogene; 2023 Feb; 42(8):601-612. PubMed ID: 36564468
[TBL] [Abstract][Full Text] [Related]
34. miR-450b-5p induced by oncogenic KRAS is required for colorectal cancer progression.
Ye YP; Wu P; Gu CC; Deng DL; Jiao HL; Li TT; Wang SY; Wang YX; Xiao ZY; Wei WT; Chen YR; Qiu JF; Yang RW; Lin J; Liang L; Liao WT; Ding YQ
Oncotarget; 2016 Sep; 7(38):61312-61324. PubMed ID: 27494869
[TBL] [Abstract][Full Text] [Related]
35. Feedback activation of EGFR/wild-type RAS signaling axis limits KRAS
Feng J; Hu Z; Xia X; Liu X; Lian Z; Wang H; Wang L; Wang C; Zhang X; Pang X
Oncogene; 2023 May; 42(20):1620-1633. PubMed ID: 37020035
[TBL] [Abstract][Full Text] [Related]
36. Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review.
Bteich F; Mohammadi M; Li T; Bhat MA; Sofianidi A; Wei N; Kuang C
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569406
[TBL] [Abstract][Full Text] [Related]
37. Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with
Ohishi T; Kato Y; Kaneko MK; Ohba SI; Inoue H; Harakawa A; Kawada M
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32839411
[TBL] [Abstract][Full Text] [Related]
38. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-543 suppresses colorectal cancer growth and metastasis by targeting KRAS, MTA1 and HMGA2.
Fan C; Lin Y; Mao Y; Huang Z; Liu AY; Ma H; Yu D; Maitikabili A; Xiao H; Zhang C; Liu F; Luo Q; Ouyang G
Oncotarget; 2016 Apr; 7(16):21825-39. PubMed ID: 26968810
[TBL] [Abstract][Full Text] [Related]
40. Exosomal long noncoding RNA CRNDE-h as a novel serum-based biomarker for diagnosis and prognosis of colorectal cancer.
Liu T; Zhang X; Gao S; Jing F; Yang Y; Du L; Zheng G; Li P; Li C; Wang C
Oncotarget; 2016 Dec; 7(51):85551-85563. PubMed ID: 27888803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
